Biopharmaceutical start-up BioAge Labs is developing a weight loss drug for older adults known as azelaprag, which is intended to be taken orally along with other weight loss drugs. According to ...

Obesity drug developer BioAge Labs (BIOA) has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at ...

BioAge shifted the drug’s focus to obesity after encouraging preclinical tests of the molecule dosed in combination with Lilly’s Zepbound showed greater weight loss than Zepbound alone.

BioAge’s NLRP3 inhibitor, code-named BGE-100, is on track for an investigational new drug application in the second half of 2025. Fortney is BioAge’s largest shareholder with a 6.7% post-IPO ...

(Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor ...

BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the targeted range at $18 per share, the weight-loss drug developer said on Wednesday.

BioAge advances obesity drug into clinical trials. ... demonstrating weight loss both as a standalone treatment and when combined with GLP-1 receptor agonists.

Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss space. The Bay Area biotech has entered an option agreement with Chinese ...

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.